Oppenheimer downgraded Procept BioRobotics (PRCT) to Perform from Outperform without a price target The shares were also downgraded this morning to Underperform at BofA. Procept lowered its 2026 revenue outlook and its strategic reorganization and launch team changes will likely to take more time to bear fruit, the analyst tells investors in a research note. Oppenheimer finds it “unclear how sticky” Procept’s bulk purchase accounts will be with the net price increase.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics price target lowered to $34 from $51 at Wells Fargo
- Procept BioRobotics downgraded to Underperform from Neutral at BofA
- PROCEPT BioRobotics: Commercial Reset Creates Near-Term Headwinds but Strengthens Long-Term Buy Thesis
- Buy Rating on Aquablation Developer: Short-Term Execution Headwinds Masking Long-Term Medtech Upside
- Closing Bell Movers: Nvidia pares post-earnings gains